Jesús Rueda Rodríguez

Jesús heads the international affairs team. He continues to lead the regulatory debates that affect IVDs at EU level. Directly involved in the discussions on the revision and recast of the IVD Directive, he is also involved in the work at the international level acting as representative to WHO, ISO and as liaison to other associations on all regulatory matters.

Linkedin
Website

Global Responsibility, Global Ethics and Compliance, Global Principles for MedTech Innovation

Ethics
4 May 2018
This blog is part of the GMTCC 2018 blog series. You can follow the conversation under #GMTCC and find more details and at gmtcc.com . Check out related blogs: Swifter, Higher, Stronger: Promoting MedTech Ethics on the Global Stage , How to create and maintain an ethical culture , Progress and new challenges after 10 years of collaboration , Distributors play key role in compliance, New industry code must safeguard independent medical education and Health data can transform our lives-but must be used wisely Trust between patients and their physicians is critical in healthcare. It empowers patients and enables them to make informed decisions knowing that their caregivers have their best interests in mind. Though the practice of medicine does vary in different parts of the world this is a universal constant. As such it is important that everyone understands how healthcare professionals interact with the industries, which provide the tools of modern medicine. The medical technology sector is one of those key industries which develops and provides novel solutions to healthcare problems old and new. The Global Medical Technology Alliance (GMTA), of which MedTech Europe is a founding member, represents the medical technology industry around the globe. We are proud to announce that the Alliance has agreed on a set of global principles of ethical business practices through a Joint Global Ethical Declaration . One of the most important missions of the GMTA has been to advance compliance and ethical business practices globally, in way that promotes innovation and enhances patient access to innovative technologies. The recognition of these principles which are universally applicable is a key step in ensuring this. The GMTA principles lay down simple and pragmatic approaches for the development of codes of ethics for industry around the world, underpinned by two simple concepts: 1) Supporting...

Why diagnostics is important in dealing with the Zika threat

Global
5 Feb 2016
In the last few weeks we have seen the emergence of a new global public health threat, the Zika Virus (ZIKV). Both the World Health Organization ( WHO ) and the European Centre for Disease Prevention and Control ( ECDC ) are monitoring the spread of the Zika, a mosquito borne arbovirus. The WHO recently declared the diseases linked to the Zika virus as a global public health emergency. Several Zika cases have been reported in Europe from people who have contracted the virus while travelling. The bigger risk however is when mosquito populations in Europe become infected and start acting as a vector for the disease. The map shows the distribution of Aedes albopictus which can become a carrier of Zika in Europe. At this stage, a lot of critical questions remain: What are the risks associated with Zika? Is there a potential link between Zika infections in pregnant women and microcephaly results in newborns? The Role of Diagnostics Developing adequate diagnostic tools becomes critical especially since Zika infections can display no symptoms or symptoms similar to other viral infections. In the short term, diagnostic tools will track the spread of the infection. Understanding how the epidemic spreads will be a critical step in controlling it. Accurate diagnostic tools will be needed to understand the relationship between Zika and microcephaly. Diagnostic tools, in the long term, will be essential in developing treatments and vaccines to combat Zika. If the link between Zika and microcephaly is confirmed, it will be equally critical to manage the potential risks during pregnancy. Detecting active Zika infections and determining the immune status of the mother with regards to Zika will be essential in reducing its impact during pregnancy. Precautionary measures are now being taken to ensure the safety of the blood donations – travellers...

New EP, new Commission, another Presidency – Where does the IVD legislation stand?

Regulation
18 Mar 2015
When the European Parliament finalised their amendments for the Proposal for a Regulation on in vitro diagnostic medical devices in October 2013, they set the scene for a process that has continued through several Council Presidencies. The continued discussions are a reflection of the complexity of the file and the need for careful consideration of the technical aspects of the text, which should lead to the creation of a positive environment for innovation, safety and patient access across Europe.

Pacing the implementation of the new IVD regulations

Regulation
12 Sep 2013
Getting the timing right for the implementation of changes is essential to ensuring that the new regulations result in a better system for IVDs rather than a bureaucratic quagmire. The sweeping changes being made to risk classification will be complex and time-consuming. The lessons learned from similar overhauls in other markets show us that a period of transition is essential to optimise the implementation of changes for the new European IVD legal framework.

Wedding bells are ringing for the proposal of new IVD regulation

Regulation
18 Sep 2012
I have always found that no matter how much a person looks forward to a change, there is still that little tad of reluctance – a fear that things may not turn out for the better. The hesitation, even if momentary, manifests itself in the simple and mundane everyday tasks like clicking install for a computer software update or taking life’s big leaps, like getting married. The concern for what the change may bring is all the greater when you didn’t really mind the way things were in the first place. From my experience, some of us in the in vitro diagnostics (IVD) industry are also experiencing a bit of such reluctance when it comes to the revision of the IVD directive. Especially when it has worked fine since 1998, so why the change? A reasonable question, but considering the differences that have arisen between the healthcare context of the late 1990s and today, it’s time that our industry give the proposal careful consideration in the lead up to its approval, taking into account the impact of each of the legislation’s proposed aspects.